Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
GAITHERSBURG, Md., Nov. 22, 2016 -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 3:30 pm U.S. Eastern Time
Location: New York Palace Hotel, New York, New York
Live webcast: novavax.com, “Investors”/ “Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
